Hepatitis C vaccine. Need of the hour

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Hepatitis C virus (HCV), identified in 1989, is an enveloped RNA virus responsible for significant global liver disease.
• Annual infections range from 3-4 million, with risks including liver cirrhosis and cancer.
• Transmission occurs via blood, unsafe injections, and healthcare procedures.

Purpose of the Study:

• To review the current landscape of Hepatitis C virus (HCV) treatment and vaccine development.
• To highlight the challenges posed by treatment costs and the absence of an effective vaccine.

Main Methods:

• Review of existing literature on HCV treatments and vaccine research.
• Analysis of treatment efficacy, costs, and transmission modalities.
• Assessment of preclinical and clinical vaccine trial progress.

Main Results:

• Standard interferon (IFN) and ribavirin therapy is pan-genotypic but costly ($20,000+ for 12 months).
• Newer direct-acting antivirals offer high cure rates but are prohibitively expensive ($82,000 per subject annually).
• No licensed HCV vaccine is currently available, though several are in preclinical and early clinical development.

Conclusions:

• High treatment costs limit access to effective Hepatitis C virus (HCV) therapies worldwide.
• Developing an accessible and effective HCV vaccine remains a critical unmet medical need.
• Further research and larger human trials are essential to evaluate promising HCV vaccine candidates.